|
1
|
p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci.
|
Nat Genet
|
2004
|
3.87
|
|
2
|
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.
|
Cell Stem Cell
|
2010
|
2.89
|
|
3
|
p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts.
|
Mol Cell
|
2005
|
2.38
|
|
4
|
Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin.
|
Dev Cell
|
2004
|
2.01
|
|
5
|
Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs.
|
Nature
|
2013
|
2.00
|
|
6
|
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
|
Proc Natl Acad Sci U S A
|
2008
|
1.80
|
|
7
|
Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation.
|
Mol Cell
|
2007
|
1.70
|
|
8
|
Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex.
|
EMBO J
|
2011
|
1.55
|
|
9
|
A systems approach reveals that the myogenesis genome network is regulated by the transcriptional repressor RP58.
|
Dev Cell
|
2009
|
1.53
|
|
10
|
Chromatin: the interface between extrinsic cues and the epigenetic regulation of muscle regeneration.
|
Trends Cell Biol
|
2009
|
1.49
|
|
11
|
Coordination of cell cycle, DNA repair and muscle gene expression in myoblasts exposed to genotoxic stress.
|
Cell Cycle
|
2011
|
1.47
|
|
12
|
Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases.
|
Proc Natl Acad Sci U S A
|
2002
|
1.36
|
|
13
|
Activation of MyoD-dependent transcription by cdk9/cyclin T2.
|
Oncogene
|
2002
|
1.33
|
|
14
|
Differentiation-induced radioresistance in muscle cells.
|
Mol Cell Biol
|
2004
|
1.30
|
|
15
|
The epigenetic network regulating muscle development and regeneration.
|
J Cell Physiol
|
2006
|
1.28
|
|
16
|
Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells.
|
Mol Cell Biol
|
2005
|
1.27
|
|
17
|
Epigenetic reprogramming of human embryonic stem cells into skeletal muscle cells and generation of contractile myospheres.
|
Cell Rep
|
2013
|
1.17
|
|
18
|
Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice.
|
EMBO Mol Med
|
2013
|
1.16
|
|
19
|
SWI/SNF complexes, chromatin remodeling and skeletal myogenesis: it's time to exchange!
|
Exp Cell Res
|
2010
|
1.10
|
|
20
|
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
|
Mol Med
|
2011
|
1.06
|
|
21
|
Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300.
|
Oncogene
|
2004
|
1.06
|
|
22
|
The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis.
|
PLoS One
|
2008
|
1.05
|
|
23
|
HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles.
|
Genes Dev
|
2014
|
1.03
|
|
24
|
Epigenetic regulation of skeletal myogenesis.
|
Organogenesis
|
2010
|
1.02
|
|
25
|
Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy.
|
FASEB J
|
2009
|
1.00
|
|
26
|
Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy.
|
Int J Biochem Cell Biol
|
2008
|
0.98
|
|
27
|
DNA damage and cellular differentiation: more questions than responses.
|
J Cell Physiol
|
2007
|
0.98
|
|
28
|
Signaling to the chromatin during skeletal myogenesis: novel targets for pharmacological modulation of gene expression.
|
Semin Cell Dev Biol
|
2005
|
0.96
|
|
29
|
Coordinate Nodal and BMP inhibition directs Baf60c-dependent cardiomyocyte commitment.
|
Genes Dev
|
2013
|
0.96
|
|
30
|
Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin.
|
J Cell Physiol
|
2003
|
0.95
|
|
31
|
MyoD recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions.
|
J Cell Physiol
|
2006
|
0.95
|
|
32
|
A two-hit mechanism for pre-mitotic arrest of cancer cell proliferation by a polyamide-alkylator conjugate.
|
Cell Cycle
|
2006
|
0.94
|
|
33
|
Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation.
|
Cell Cycle
|
2011
|
0.93
|
|
34
|
A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels.
|
Cell Mol Life Sci
|
2013
|
0.93
|
|
35
|
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
|
Mol Med
|
2013
|
0.92
|
|
36
|
An evolutionarily acquired genotoxic response discriminates MyoD from Myf5, and differentially regulates hypaxial and epaxial myogenesis.
|
EMBO Rep
|
2011
|
0.92
|
|
37
|
SIRT1 signaling as potential modulator of skeletal muscle diseases.
|
Curr Opin Pharmacol
|
2012
|
0.89
|
|
38
|
Epigenetic control of skeletal muscle regeneration: Integrating genetic determinants and environmental changes.
|
FEBS J
|
2013
|
0.89
|
|
39
|
Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma.
|
Cancer Biol Ther
|
2003
|
0.87
|
|
40
|
Phosphoryl-EZH-ion.
|
Cell Stem Cell
|
2011
|
0.84
|
|
41
|
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
|
BMC Cancer
|
2014
|
0.83
|
|
42
|
Myosin phosphatase modulates the cardiac cell fate by regulating the subcellular localization of Nkx2.5 in a Wnt/Rho-associated protein kinase-dependent pathway.
|
Circ Res
|
2012
|
0.82
|
|
43
|
Epigenetic drugs in the treatment of skeletal muscle atrophy.
|
Curr Opin Clin Nutr Metab Care
|
2008
|
0.80
|
|
44
|
Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways.
|
Eur J Cancer
|
2011
|
0.79
|
|
45
|
HDACs and sirtuins: targets for new pharmacological interventions in human diseases.
|
Pharmacol Res
|
2010
|
0.76
|
|
46
|
Switch NFix developmental myogenesis.
|
Dev Cell
|
2010
|
0.75
|
|
47
|
Epigenetic control of reprogramming and cellular differentiation.
|
Comp Funct Genomics
|
2012
|
0.75
|